GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Inc (ROCO:6892) » Definitions » EBITDA Margin %

Taiwan Bio Therapeutics (ROCO:6892) EBITDA Margin % : -96.44% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Taiwan Bio Therapeutics's EBITDA for the three months ended in Dec. 2024 was NT$-63.30 Mil. Taiwan Bio Therapeutics's Revenue for the three months ended in Dec. 2024 was NT$65.64 Mil. Therefore, Taiwan Bio Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was -96.44%.


Taiwan Bio Therapeutics EBITDA Margin % Historical Data

The historical data trend for Taiwan Bio Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics EBITDA Margin % Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial - -215.18 -289.34 -170.79 -235.40

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -314.11 -29.43 - -826.11 -96.44

Competitive Comparison of Taiwan Bio Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Taiwan Bio Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Bio Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics's EBITDA Margin % falls into.


;
;

Taiwan Bio Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Taiwan Bio Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-247.391/105.094
=-235.40 %

Taiwan Bio Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-63.303/65.642
=-96.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taiwan Bio Therapeutics  (ROCO:6892) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Taiwan Bio Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.

Taiwan Bio Therapeutics Headlines

No Headlines